Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Nov 4 - Nov 9
In the head-to-head SURMOUNT-5 trial, Zepbound produced significantly greater weight loss an average of 20.2% versus 13.7% for Wegovy over 72 weeks, a 47% greater relative reduction
Canadian Medical Association Journal 172(7): 873
Research on the risk of acute pancreatitis in people taking GLP-1 receptor agonists like semaglutide has shown mixed results
Based on published data, retatrutide results show a mean weight loss of up to 28.3% to 28.7% at maximum doses over 68 to 80 weeks
Reviews are checked for mixing, smell, packaging, and refusal issues
US$ 28.56
US$ 25.49
US$ 24.69
US$ 22.23
